Summary.-BDF' mice were inoculated with 106 leukaemic cells and, together with control mice, were given a single oral dose of cyclophosphamide-14C of 100 mg/kg body weight. In the leukaemic mice we observed an increased'4C concentration in the plasma, bone marrow, liver, lungs, spleen, kidney and particularly fat where the level was 2-4 times higher than in control mice. Conversely, during the same period, significantly less 14C was detected in the stomach and small intestine of the leukaemic mice. These results were obtained 6 days after tumour transplantation (median survival time 7*7 days) whereas no differences were observed when the studies were carried out 4 days after tumour transplantation. These findings indicate an increase in the gastrointestinal absorption and in the tissue storage of cyclophosphamide in L-1210 leukaemic mice at an advanced stage of the disease.
CYCLOPHOSPHAMIDE is used in the treatment of a variety of human tumours, including Hodgkin's disease and lymphomata, multiple myeloma and chronic and acute leukaemia (Gershwin, Goetzl and Steinberg, 1974) . Besides the fact that the drug must be metabolized by the liver before exerting its cytotoxic activity Hohorst, 1962, 1967; Cohen and Jao, 1970; Brock et al., 1971) , other factors such as absorption and selective storage in some tissues might influence the quality and duration of cyclophosphamide activity.
Such an hypothesis has led us to try to establish, in BDF1 mice inoculated with L-1210 leukaemia cells, a relationship between the plasma concentration of cyclophosphamide, its gastrointestinal absorption and its storage in some tissues. The tests have been performed at an advanced stage of the disease, with appropriate controls.
To our knowledge, there is no published study in which the metabolism of cyclophosphamide has been measured with a strict control over the stage of the disease. This has been achieved by consideration of the following parameters: survival time, volume of ascitic fluid, body weight, liver and spleen weights.
MATERIALS AND METHODS
Animals.-The first strain of L-1210 leukaemic mice were DBA/2 mice generously supplied by the National Institute of Health (Bethesda, U.S.A.). In ascitic form, the L-1210 leukaemia was maintained by weekly transplantations into BDF1 male mice (C57BL/6 Y x DBA/2 ,) obtained from ARS Corp., Canada. Non-radioactive cyclophosphamide (Procytox) was mixed with cyclophosphamide-14C in distilled water and a dose of 100 mg/kg containing about 1 ,tCi was given orally to each mouse. The purity of both compounds was checked by thin layer chromatography; 20 ,ul of either solution (non-radioactive, radioactive) -%Aere spotted on silica gel plates and the migration performed in a bath containing a solvent mixture of n-butanol-acetic acid-water (6: 2 : 2) according to the technique of Bus, Short and Gibson (1973) . The chromatograms were developed with NBP and KOH reagents (Friedman and Boger, 1961; Hill, Laster and Struck, 1972) ; for 14C, the radioactivity (plate divided in 1 cm sections) was measured in a cocktail of 1 ml of methanol plus 15 ml of toluene scintillator containing POPOP and PPO (Bus et al., 1973) .
Blue spots, indicating presence of alkylating metabolites, were not detected either for unlabelled cyclophosphamide or for the radioactive compound. For cyclophosphamide-14C there was a single peak of radioactivity that gave an Rf of 0-72.
Drug administration. Six days after tumour transplantation, the mice were given cyclophosphamide-14C orally using a single dose of 100 mg/kg (about 1 pCi/mouse). 
RESULTS
Our criteria to evaluate the period (evolution) of the disease were the following: (1) median survival time ( Fig. 1 ) which was 7-7 days for 101 mice; (2) body weight ( Fig. 2) : the control mice gained 2 g a week compared with 4-1 g for leukaemic mice; (3) the ascitic fluid which is present from the 4th day after tumour transplantation and whose quantity reaches a maximum at the 6th and 7th days; (4) hepatomegaly and splenomegaly (Table I) In plasma (Fig. 3 ) the disappearance curve of the drug is quite similar in both groups. The curves indicate that the gastrointestinal absorption is fast, with a peak concentration in the plasma occurring between 5 and 15 min. After 6 h, the plasma is almost free of the drug. Except at the 5 min reading, the plasma concentration of 14C is always significantly higher in the leukaemic group.
The 14C present in the bone marrow from both femurs (Fig. 4) In fat taken from the epididymal area (Fig. 5) there is a striking accumulation of 14C by the leukaemic mice compared with control mice in which there is a constant concentratioh up to 60 min, followed by a slow release. Unlike the other tissues, the peak concentration for the leukaemic group is at 30 min, at which interval the 14C concentration is 4 times higher than in the control group.
In other tissues (Fig. 6) there is again an overall higher 14C concentration in the leukaemic group and where there is not, the differences are not significant. Kidney shows the highest concentration, being the principal site of excretion for cyclophosphamide. Lungs, which are richly vascularized, may reflect the blood concentration, even though some unknown metabolites might be excreted by this route. The liver retains the second For the gastrointestinal absorption of cyclophosphamide the results are expressed as the percentage of d/min (14C) found in the stomach or small intestine, or both. In the content and tissue of the stomach (Fig. 7) we found less '4C in the leukaemic group at every point except 60 min, where the findings are not significant. In the same Figure it can be seen that the small intestine (content and tissue) also contains significantly less 14C in the leukaemic group, except at 5 and 360 min.
Finally, in Fig. 8 (Fig. 1) so that at the 6th day the mice were at the terminal stage. The reddish colour, together with the quantity of ascitic fluid (2-3 ml), constituted 2 additional criteria confirming the evolution of the disease. By the 4th day ascitic fluid was present in the peritoneal cavity and it was very likely the main cause for the increase in body weight (Fig. 2) (Bus et al., 1973) . In normal mice the clearance of alkylating activity from the blood after a 180 mg/kg intraperitoneal dose was virtually complete within 3 h and alkylating metabolites reached peak plasma concentration at 10-15 min (Gibson and Becker, 1968; Field et al., 1972) .
In the bone marrow sampled from the 2 femurs (Fig. 4) an interesting finding was the significant increase in radioactivity, except at 5 min, in leukaemic mice. This could not be simply a reflexion of plasma concentration since an almost constant level of 14C has been found between 60 and 360 min, a fact that seems to indicate a selective concentration of the drug at its main site of cytotoxical action (Greenwald, 1973) .
The strong increase in radioactivity in the fat tissues of the leukaemic mice (Fig. 5) should be stressed. It is [2] [3] [4] times that of the control mice. The fact might be explained in 2 ways: either leukaemic mice have an increased capacity for storing the drug in their fat tissues, due to mechanisms presently unknown, or there might be a decreased biotransformation of cyclophosphamide in the liver so that the drug itself would con- Control mice: * *, leukaemic mice: 0 ----. * P < 0 05. centrate in the fat tissues, in lieu of its own metabolites. As demonstrated by several authors, the liver drug metabolizing enzyme activity is reduced in tumour bearing animals, leading to increased levels of unchanged drug and increased pharmacological effect or toxicity Kato, Takanaka and Oshima, 1968; Rosso, Dolfini and Donelli, 1968; Rosso et al., 1971; Bartosek et al., 1975; Fabro, 1971, 1975) . Such a comparison between control and leukaemic mice is interesting because until now unusually high localization of cyclophosphamide in a specific organ has not been reported (Torkelson, LaBudde and Weikel, 1974 (Fig. 6) . Whereas the plasma disappearance curve had indicated a rapid absorption of the drug with a peak at 15 min, the concentration of 14C in the kidneys, which constitute the principal excretory pathway for cyclophosphamide in several animal species (Torkelson et al., 1974) as in man (Bagley, Bostick and DeVita, 1973) , would seem to indicate a rapid elimination. However, it had been noted that in mice (Torkelson et al., 1974) tion in the liver can be explained by the important role played by this organ in the biotransformation of cyclophosphamide into cytotoxic alkylating metabolites Hohorst, 1962, 1967; Cohen and Jao, 1970; Brock et al., 1971; Sladek, 1972) . In mice, the initial oxidative step in cyclophosphamide metabolism is performed by the microsomal mixed function oxidase system of the liver to yield 4-hydroxy cyclophosphamide (Sladek, 1972) which is converted to aldophosphamide; aldophosphamide is very toxic to L-1210 leukaemia cells (Hill et al., 1972) and is further oxidized, probably by liver aldehyde oxidase, to carboxyphosphamide, a metabolite which has little or no anti-tumour effect on L-1210 cells (Hill et al., 1972) . More recently, volatile metabolites, possibly produced within the tumour cell but not in the liver, have been isolated, e.g. acrolein (Thomson and Colvin, 1974) and phosphoramide mustard (Connors et al., 1974) ; these 2 metabolites are toxic to L-1210 leukaemia cells and Walker tumour cells. From these studies it appears that the complex mode of activation of cyclophosphamide is not completely resolved (Chabner et al., 1975) and that at least 2 of the known active metabolites (aldophosphamide and acrolein) are indeed labelled with the ring 5-14C material used in our study (see Fig. 8 in Cliabner et al., 1975) .
In the past few years it has been demonstrated that Ehrlich ascites tumour bearing mice (Beck et al., 1975) or spontaneous tumour bearing mice (Sharma and Garb, 1974) as well as Walker 256 carcinoma bearing rats (Rosso et al., 1968; Franchi and Rosso, 1969) According to our findings with cyclophosphamide, the increased plasma and tissue radioactivity concentration in leukaemic mice could be explained by an increase in the absorption of cyclophosphamide at the gastric level as well as at the small intestine level (Fig. 7) (see Fig. 8 for a summary) . The hypothesis might be advanced that an increase in gastrointestinal motility would facilitate the transit of the drug and accelerate its passive diffusion to the blood. There may also be an increased blood flow at the level of the gastrointestinal tract in leukaemic mice. The actual mechanism remains to be demonstrated. XVe may add, from the data appearing in Table II , that a definite correlation can hardly be made between the degree of tissue infiltration by malignant cells and drug uptake by the same tissues.
It is important to note that the experiments were also performed on leukaemic mice 4 days after the inoculation of 106 leukaemic cells and that, at that stage, there was no difference between leukaemic and control mice as far as the metabolism (gastrointestinal absorption, plasma and tissue concentration) of cyclophosphamide was concerned.
In conclusion, our findings confirm the importance of a pharmacokinetic approach in the study of antineoplastic drugs (Balconi et al., 1973; Bischoff, 1973; Mellet, 1974; Bossi et al., 1975) even if it is well known that the efficacy of cyclophosphamide is dependent on its biotransformation by the liver (Sladek 1972 
